Target Price | $9.14 |
Price | $1.10 |
Potential |
731.17%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Caribou Biosciences 2026 .
The average Caribou Biosciences target price is $9.14.
This is
731.17%
register free of charge
$32.00
2,809.09%
register free of charge
$1.00
9.09%
register free of charge
|
|
A rating was issued by 9 analysts: 7 Analysts recommend Caribou Biosciences to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Caribou Biosciences stock has an average upside potential 2026 of
731.17%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 9.99 | 9.92 |
71.03% | 0.72% | |
EBITDA Margin | -1,628.53% | -1,563.04% |
398.99% | 4.02% | |
Net Margin | -1,536.04% | -1,194.04% |
312.67% | 22.26% |
8 Analysts have issued a sales forecast Caribou Biosciences 2025 . The average Caribou Biosciences sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Caribou Biosciences EBITDA forecast 2025. The average Caribou Biosciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Caribou Biosciences Analysts have issued a net profit forecast 2025. The average Caribou Biosciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.65 | -1.27 |
19.57% | 23.03% | |
P/E | negative | |
EV/Sales | negative |
3 Analysts have issued a Caribou Biosciences forecast for earnings per share. The average Caribou Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Caribou Biosciences...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Nov 26 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 03 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 28 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 07 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Nov 26 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 15 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 03 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.